MPN (Myeloproliferative Neoplasms) Clinical Trial
Official title:
An Open-Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post- Essential Thrombocythemia Myelofibrosis, and Post-Polycythemia Vera Myelofibrosis Who Have Platelet Counts of 50 × 10^9/L to 100 × 10^9/L
To evaluate the effects of treatment with ruxolitinib (INCB018424) on spleen volume, symptoms and potential side effects in participants with PMF, PPV-MF and PET-MF who have platelet counts of 50 x 10^9/L to 100 x 10^9/L. It is anticipated that individualized dose optimization from the starting ruxolitinib level of 5 mg bid will be associated with reductions in splenomegaly, MF-associated symptoms and inflammatory cytokine levels.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03123588 -
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
|
Phase 2 | |
| Completed |
NCT02252159 -
Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)
|
||
| Completed |
NCT01633372 -
An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis
|
Phase 2 | |
| Completed |
NCT03144687 -
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis
|
Phase 2 | |
| Completed |
NCT02718300 -
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
|
Phase 2 | |
| Completed |
NCT02953704 -
Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)
|
||
| Completed |
NCT00952289 -
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
|
Phase 3 | |
| Active, not recruiting |
NCT03011372 -
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
|
Phase 2 |